Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis And China’s MOH Collaborate On Healthcare Safety And Hospital Management Program

This article was originally published in PharmAsia News

Executive Summary

Novartis China and partners Harvard Medical International, the International Health Exchange and Cooperation Center under China's Ministry of Health recently kicked off an academic exchange and collaboration program. The three-year program includes two major conference themes - healthcare safety and hospital top management forum and a Chinese hypertension expert summit. PHMI and Novartis will, according to the field's local and international issues, plan meeting topics and invite authorities in charge of healthcare policies from China and overseas healthcare institutions. The platform seeks to introduce local medical developments as well as share the latest global management experience and best practices in healthcare treatment. (Click here for more - Chinese language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC071315

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel